(Reuters) – Moderna Inc said on Monday it has dosed the first patient in an early-stage study of its COVID-19 vaccine candidate, being evaluated as a potential booster shot for previously vaccinated people.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)
